Sen. Tina Smith Sells Off Shares of DexCom, Inc. (NASDAQ:DXCM)

Senator Tina Smith (Democratic-Minnesota) recently sold shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in DexCom stock on April 29th.

Senator Tina Smith also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 4/29/2026.
• Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
• Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.

DexCom Stock Up 1.3%

Shares of DexCom stock traded up $0.78 during trading on Tuesday, hitting $60.11. 737,418 shares of the stock traded hands, compared to its average volume of 4,903,241. The stock has a market cap of $23.20 billion, a P/E ratio of 25.68, a PEG ratio of 1.04 and a beta of 1.40. The company has a fifty day moving average price of $64.54 and a two-hundred day moving average price of $66.16. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.32 earnings per share. Equities research analysts predict that DexCom, Inc. will post 2.56 EPS for the current fiscal year.

Institutional Investors Weigh In On DexCom

Hedge funds and other institutional investors have recently modified their holdings of the stock. Trust Co. of Vermont raised its stake in DexCom by 14.8% during the 4th quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 145 shares during the last quarter. CVA Family Office LLC increased its holdings in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after purchasing an additional 147 shares during the period. V Square Quantitative Management LLC increased its holdings in shares of DexCom by 1.8% during the 1st quarter. V Square Quantitative Management LLC now owns 9,618 shares of the medical device company’s stock worth $604,000 after purchasing an additional 172 shares during the period. Essex Financial Services Inc. lifted its stake in shares of DexCom by 5.7% in the first quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical device company’s stock valued at $204,000 after buying an additional 175 shares during the period. Finally, IFP Advisors Inc lifted its stake in shares of DexCom by 24.7% in the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after buying an additional 178 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on DXCM. Evercore raised shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 target price on the stock in a research report on Tuesday, March 24th. Barclays set a $67.00 price objective on shares of DexCom and gave the stock an “underweight” rating in a report on Friday, May 1st. Truist Financial reiterated a “buy” rating and issued a $80.00 target price (down from $82.00) on shares of DexCom in a research note on Tuesday, February 17th. TD Cowen dropped their target price on shares of DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Finally, Piper Sandler restated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and an average target price of $83.22.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the sale, the executive vice president owned 111,204 shares in the company, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.28% of the stock is currently owned by company insiders.

About Senator Smith

Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.